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Abstract 42 
Objective 43 
Determine the challenges in diagnosis, monitoring, support provision in the management of 44 
IBD patients and explore the adaptations of IBD services.  45 
Methods 46 
Internet based survey by invitation of IBD services across the United Kingdom from 8th to 47 
14th April 2020 48 
Results 49 
Respondents from 125 IBD services completed the survey. The number of whole-time 50 
equivalent (WTE) gastroenterologists and IBD nurses providing elective outpatient care  51 
decreased significantly between baseline (median 4, IQR 4-7.5 and median 3, IQR 2-4) to the 52 
point of survey (median 2, IQR 1-4.8 and median 2, IQR 1-3) in the 6 week period following 53 
the onset of the COVID-19 pandemic (p<0.001 for both comparisons). Almost all (94%; 54 
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112/119) services reported an increase in IBD helpline activity. Face-to-face clinics were 55 
substituted for telephone consultation by 86% and video consultation by 11% of services. A 56 
variation in the provision of laboratory faecal calprotectin testing was noted with 27% of 57 
services reporting no access to faecal calprotectin, and a further 32% reduced access. There 58 
was also significant curtailment of IBD specific endoscopy and elective surgery. 59 
Conclusions 60 
IBD services in the UK have implemented several adaptative strategies in order to continue to 61 
provide safe and high-quality care for patients.  NHS organisations will need to consider the 62 
impact of these changes in current service delivery models and staffing levels when planning 63 
exit strategies for post-pandemic IBD care. Careful planning to manage the increased 64 
workload and to maintain IBD services is essential to ensure patient safety.  65 
Summary box 66 
What is known on the subject 67 
• COVID 19 pandemic is expected to pose a myriad of challenges to NHS services. 68 
• Essential services for IBD patients including outpatient care, advice lines, endoscopy 69 
and infusion units may be affected 70 
What this study adds 71 
• This survey evaluates the challenges to IBD services during the pandemic and the 72 
adaptations to meet these challenges.  73 
• There is significant reduction in staffing resources for the IBD team and significant 74 
increase in IBD advice line contact.  75 
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• Face to face consultations in outpatients, non-emergency endoscopies and elective 76 
IBD have been significantly curtailed. 77 
•  There is increased uptake of telemedicine, virtual MDTs and non-invasive 78 
monitoring of patients. 79 
How it might impact clinical practice in the foreseeable future  80 
• There is urgent need to review models of care and staffing levels of IBD service in 81 
planning exit strategies in the post pandemic period. 82 
• Insights gained from the rapid adaptations by services during the peak of the 83 
pandemic may present opportunities for positive changes in IBD services  84 
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Introduction 85 
The COVID-19 pandemic has significant implications for the diagnosis and management of 86 
patients with gastrointestinal conditions including inflammatory bowel disease (IBD)[1]. 87 
Health care systems have had to adapt rapidly to maintain provision of core services and 88 
reduce unintended consequences from the necessary diversion of resources to focus on the 89 
pandemic. The continued accumulation of cases positive for SARS-CoV-2 and the 90 
intervention from national governments to enforce strict social isolation (‘shielding’) and 91 
distancing have necessitated IBD services to dramatically changing and restructuring the way 92 
they provide care for IBD patients [2]. In addition, the rapid increase in COVID-19 93 
hospitalisations along with restrictions in endoscopic and surgical facilities has resulted in the 94 
redeployment of clinicians and nurses to front line services to care for these patients with 95 
resultant impact on the delivery of IBD care [3]. In IBD, delays in diagnosis and therapy can 96 
have serious consequences including the need for emergency surgery [4].  97 
Patients are understandably concerned about the impact of their IBD and its treatment on 98 
their risk of severe COVID-19 disease. However, it is important that IBD patients continue to 99 
attend for inpatient, day case and outpatient hospital care for the management of active 100 
disease and complications, and for therapies such as intravenous biologics. Furthermore, 101 
given that immunosuppressive and biologic agents form the cornerstone of IBD management, 102 
concerns have been raised that patients with IBD may be more susceptible to SARS-CoV-2 103 
infection and whether they may have poorer outcomes if infected with the virus [5,6]. 104 
Although, there are, as yet, no specific data quantifying additional risk, specialist societies 105 
and expert groups have recommended heightened vigilance [7–9]. In the UK, patients 106 
categorised as high risk have been recommended for isolation (‘shielding’) by UK 107 
Department of Health and Social Care [10], requiring individual IBD services to rapidly 108 
identify individuals in this group using hospital databases and registries.  109 
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The UK has a strong record of providing personalised multidisciplinary care for patients with 110 
IBD. Successive IBD audits have shown improvements in resource provision (including IBD 111 
nurses) and overall quality of care [11,12]. More recently, a multidisciplinary stakeholder 112 
group has proposed key quality standards for IBD care in the UK [13]. Maintaining high-113 
quality care during the COVID-19 pandemic will remain a constantly evolving challenge. 114 
IBD clinicians and specialist nurses across the UK have formed an IBD COVID-19 working 115 
group to share expertise and promote a collaborative and co-ordinated nationwide approach 116 
to meeting the challenges posed by the pandemic. This has enabled the development of a UK 117 
consensus on management of IBD during the COVID-19 pandemic [8].  118 
The impact of the COVID-19 pandemic on provision of IBD care has not been previously 119 
evaluated. Most centres have rapidly and independently reconfigured their services guided 120 
bylocal management decisions based on varying service needs, redeployment of some of their 121 
staff, and re-configuration of available healthcare facilities. There has been limited 122 
opportunity or time to share experience of service reconfiguration to determine the impact 123 
across regions. We surveyed adult and paediatric gastroenterology services caring for IBD 124 
patients in the UK to assess the impact of COVID-19 on service-delivery.  125 
Methods 126 
We developed an internet-based survey using Google Forms (Google, CA, USA) to assess 127 
changes to IBD service provision in the COVID-19 period. This was circulated to IBD 128 
services throughout the UK through the membership of the UK IBD COVID-19 working 129 
group and social media. The Royal College of Nursing (RCN) IBD specialist nurse network 130 
and the service leads of the services participating in the IBDUK self-assessment were also 131 
invited to participate. Furthermore, the survey was e-mailed to the membership of the British 132 
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Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN). Survey 133 
participation was voluntary, and the option was given to provide the NHS Trust identity and 134 
contact details with the option of being contacted for future surveys related to this subject. 135 
The survey was carried out between 8th to 14th April 2020 which corresponded to 1 month 136 
after the UK government decision for lockdown. The survey (included in appendix) covered 137 
the characteristics and staffing resources of the services, the changes instituted in provision of 138 
IBD care in preparation for the COVID-19 pandemic and the impact of the pandemic on the 139 
provision of IBD services. Data was collected in Google Docs and then exported for analysis 140 
to Microsoft Excel (Microsoft, WA, USA) and R 3.6.0 (R Foundation for Statistical 141 
Computing, Vienna, Austria). Where more than one response was received from the same 142 
IBD service, the most recent response was used, though paediatric and adult services were 143 
counted as separate. Response frequencies were tabulated and expressed as percentages of 144 
total responses; where there were incomplete responses to a question, this is reflected in the 145 
relevant denominator. Wilcoxon signed rank tests were used to compare paired continuous 146 
variables. Fisher’s exact test was used to compare categorical data. 147 
Results 148 
Respondents  149 
We received 147 responses representing 125 IBD services (England 106, Scotland 9, Wales 150 
8, and Northern Ireland 2) representing approximately 70% of the IBD services in the UK, 151 
(paediatric services 19% of the total). Respondents included 65 (44%) adult 152 
gastroenterologists, 53 (36%) adult IBD nurses, 21 (14%) paediatric gastroenterologists, 6 153 
(4%) paediatric IBD nurses and 1 IBD surgeon.  Only the most recent response for each 154 
service was used. Fifty-seven percent (71/124) were dedicated IBD services and 43% 155 
(53/124) were general gastroenterology services providing IBD care. Fifty-seven percent 156 
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(70/123) of the services were based in a university teaching hospital while 42% (52/123) 157 
were based in district general hospitals. All services who responded were based in public 158 
hospitals in the UK National Health Service (NHS). 159 
Impact on work force 160 
The overall number of whole-time equivalent (WTE) gastroenterologists and IBD nurses 161 
providing elective outpatient care decreased significantly between baseline (median 4, 162 
interquartile range [IQR] 4-7.5 and median 3, IQR 2-4) to the point of survey (median 2, IQR 163 
1-4.8 and median 2, IQR 1-2) six weeks following the onset of the COVID-19 pandemic  164 
(p<0.001 for both comparisons). The proportion of services with more than 3 WTE 165 
gastroenterologists providing IBD care was 81% (100/124) at baseline but fell to 34% 166 
(41/122) as a result of reconfiguration (p<0.001), with 8% (10/122) services having no 167 
dedicated IBD clinician in the COVID-19 era. Similarly, the number of services with more 168 
than one WTE IBD nurse fell from 81% (100/124) to 53% (63/118) (p<0.001). Eight percent 169 
(9/118) of services stated that they had no provision for IBD nurse care. The main reasons 170 
given for the reduction in gastroenterologists and IBD nurses were redeployment (51% 171 
[64/125] and 40% [50/125] respectively), self-isolation due to COVID-19 symptoms (22% 172 
[27/125] and 17% [21/125]) and belonging to the shielding category (9% [11/125] and 14% 173 
[18/125]). The number of WTE nurses in adult IBD services dropped significantly from 174 
median 3 (IQR 2-4) to 2 (IQR 1-3, p-value <0.001). In paediatric services, the median 175 
number of nurses was 2 (IQR 1-2) prior to COVID-19 and 1 (IQR 1-2) in the COVID-19 era 176 
(p=0.24).  177 
The median number of WTE gastroenterologists and IBD nurses required to provide IBD 178 
care for adult patients as self-assessed by our respondents were 4.0 (IQR 2.4-5.0) and 3.0 179 
(2.0-4.0) respectively. For paediatric services, the median number of WTE 180 
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gastroenterologists and IBD nurses required to provide IBD care was reported as 2.0 (IQR 181 
1.0-3.0) and 1.0 (1.0-2.0) respectively. When asked about the possibility of reduction in staff 182 
numbers below this required number as a result of COVID-19, 60% (72/119) of services 183 
thought this was certain or highly likely for gastroenterologists and 63% (70/123) for IBD 184 
nurses (Figure 1) 185 
Only 7% (9/125) of services reported that their IBD nurses could maintain their normal 186 
service. IBD specialist nursing support for inpatients was either not available for 26% 187 
(32/125) or curtailed by 31% (39/125) of the services. Similarly, nurse-led out-patient clinics 188 
had been suspended by 27% (34/125) and reduced in a further 26% (33/125) of services. 189 
Impact on IBD Service Functions 190 
Clinics 191 
Significant changes were reported in the provision of outpatient IBD clinics. No service 192 
reported continuing normal activity with routine face to face appointments. Nine percent of 193 
services reported running face-to-face clinics with reduced capacity, and 30% (38/125) 194 
reported complete cancellation of routine clinics. Face-to-face clinics were substituted with 195 
telephone consultation by 86% (108/125) and video consultation by 11% (14/125) of 196 
services; most services (13/14) using video were also using telephone consultations. The 197 
proportion of patients reviewed using telephone clinics was 100% in half of services (61/124) 198 
and above 50% in a further 32% (40/124). In contrast, only 19% of services (23/123) reported 199 
having access to video consultation, with the majority  (20/25) having access to video 200 
facilities reporting that they used them for less than a fifth of their consultations.  We 201 
observed the use of patient apps in some services with 6% (7/123) and 14% (17/123) of 202 
respondents respectively reporting current use or in set up. 203 
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Infusion Services 204 
Drug infusion services were re-located to a ‘safer area’ away from acute services by 50% 205 
(62/125). The majority, 62% (77/125), reported performing a pre-screening check list for 206 
COVID-19 before patients were invited to attend infusion services for treatment. Most 207 
services (77%, 96/125) reported maintaining infusion intervals with “enhanced provisions” to 208 
reduce transmission but 11% (14/125) reported delaying treatment. Masks were reported as 209 
being used by staff in 61% (76/125) of services and by patients in 24% (30/125). Seven 210 
percent (9/125) of services reported proactively switching their patients from intravenous to 211 
subcutaneous biologics. Sixty-two percent (78/125) of services reported patient-initiated 212 
cancellation of at least some infusions; the most frequently reported proportion was 213 
approximately 10% of patients. Patient reported reasons for cancellation included self-214 
isolation due to COVID-19 symptoms and fears and concerns about therapies. Iron infusion 215 
services have been completely stopped by 16% (20/125) or curtailed by 45% (56/125) of 216 
services respectively.  217 
IBD Advice Line  218 
The  majority of services (94%; 112/119) report an increase in IBD advice line activity, with 219 
80% (95/119) reporting a more than 50% increase and 34% (41/119) reporting a more than 220 
doubling of activity (figure 2). 221 
Services are adapting to this increased demand using strategies such as an automated e-mail 222 
(41%; 51/125); voice message response (45%; 56/125); more contact options (12%; 15/125) 223 
and additional staff overseeing/providing IBD advice line services (10%; 13/125). 224 
Conversely, 29% (36/125) have reported a reduction in the number of staff providing advice 225 
line advice. 226 
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Homecare services 227 
Twenty-seven percent (33/121) of services reported an inability to set up new home care 228 
services for subcutaneous biologics and immune-modulatory therapy. In addition, 20% 229 
(25/122) also experienced disruption to the home care delivery provision of therapies due to 230 
provider issues (28%; 3/125), blood monitoring issues (5%; 6/125); pharmacy issues (4%; 231 
5/125); and a reduced number of nurses (5%; 6/125). 232 
Endoscopy 233 
In keeping with national guidance [14], endoscopy activity has been significantly curtailed 234 
for IBD patients with current provision only being available for defined high priority 235 
indications (Figure 3). In 35% (44/125) of services all IBD-related endoscopy activity has 236 
been cancelled. 237 
Provision of IBD surgery 238 
Potential elective  surgery for IBD has been put on hold/withheld in all services surveyed. 239 
Indications for surgery that may be permitted include emergency small bowel resections in 240 
74% of services (93/125), colectomy for acute severe colitis in 72% (90/125), perianal 241 
surgery in 42% (52/125) and colectomy for IBD dysplasia in 4%; (5/125). In 10% (13/125) of 242 
services all IBD surgery has been stopped.  243 
IBD Multidisciplinary Team Meetings (MDTs) 244 
All IBD MDT meetings have been cancelled in 28% (34/122) of the services while 40% 245 
(49/122) have converted them to virtual MDTs. Twenty-five percent (30/122) of services are 246 
still running face-to-face MDT meetings, but with reduced capacity and/or social distancing. 247 
A small proportion either have put in place alternative arrangements (2%; 3/122) or never had 248 
MDTs to start with (5%; 6/122). 249 
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Laboratory services 250 
Less frequent blood monitoring regimens for patients on immunomodulators have been 251 
adopted by 65% (79/121) of services while 6% (7/121) have stopped all routine blood 252 
monitoring. The remainder of services (29%; 35/12) reported they were continuing normal 253 
monitoring arrangements. 254 
There was significant variation in the provision of laboratory faecal calprotectin testing. A 255 
quarter of services (33/122) have no access to faecal calprotectin, while a further 32% 256 
(39/122) have reduced access. Point of care calprotectin has been introduced in 5% (6/120) of 257 
services and scaled up in 2% (3/120); however, most services do not have access to point of 258 
care calprotectin analysis. 259 
Flare services 260 
Only half of the services (50%; 63/125) are providing access to face-to-face flare clinics. 261 
However, 77% (96/125) have access to blood tests in secondary care, and 62% (77/125) to 262 
blood tests in primary care while 12% (15/125) of services report no access at all to blood 263 
tests for flare. Fifty-eight percent (73/125) had access to faecal calprotectin testing (home or 264 
laboratory for flare management)s. Endoscopy was only being used to assess suspected flares 265 
in outpatients with known IBD in 6% (8/125) of services. 266 
Identification of high-risk patients  267 
The UK Government introduced guidance on 21st/22nd March 2020 to protect patients at risk 268 
of contracting COVID-19 based on emerging world data/medical advice.  The concept of 269 
shielding was introduced, requesting patients in the highest risk category to withdraw from 270 
society in their own homes for a period of 12 weeks. To support this endeavour, specialist 271 
societies including the British Society of Gastroenterology developed guidance to risk stratify 272 
patients [8]. NHS trusts and health boards then had to identify the highest risk patients based 273 
  
IBD services during COVID-19 
   
 
on these criteria. At the time of the survey, 61% (76/125) of services reported having 274 
undertaken identification of high-risk patients who meet the criteria for shielding in their IBD 275 
cohorts and 76% (95/125) have already communicated with their highest risk patients. 276 
Furthermore, 34% (42/125) of the services have communicated with their moderate risk 277 
patients. Seventy eight percent of services (96/123) reported an intention to participate in the 278 
SECURE-IBD registry (https://covidibd.org), which is recording the number of COVID cases 279 
in IBD patients; this includes 11% (14/123) who had already entered patients. 280 
Geographic variation 281 
Exploration of the variation in provision of services around the UK, including faecal 282 
calprotectin, endoscopy and surgery, did not reveal any particular clustering of loss of service 283 
into one region of the country (Figure 4). 284 
Discussion 285 
The COVID-19 pandemic is having a pronounced impact on the lives of patients and health 286 
care professionals (HCPs). IBD services in the UK meanwhile, have also needed to adapt 287 
their priorities rapidly and modify current models of service to ensure delivery of a minimum 288 
standard of safe and effective care. This involved an urgent redesign of clinical services with 289 
clear communication among HCPs to develop an iterative model of care, responsive to the 290 
challenges posed by the unpredictable pandemic.  The aim of this survey from the UK IBD 291 
COVID-19 working group was to explore, consider and disseminate examples of dynamic 292 
models of service provision. 293 
Dramatic and significant reductions in staffing levels have inevitably impacted negatively on 294 
service provision and delivery. This has affected routine care for people with IBD including 295 
disease and treatment monitoring, clinical and endoscopic assessment, endoscopic 296 
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surveillance, access to elective and semi-urgent surgery and multidisciplinary team working. 297 
Despite this, most services have been able to adapt and have been innovative with service 298 
delivery and models of care with the aim of providing safe and effective care.  299 
The unprecedented scale of this pandemic and uncertainties driven by the absence of 300 
“effective” treatment for COVID-9 has important implications for contingency planning with 301 
existing, evolving and aspirational models of care delivery. Important elements such as 302 
staffing levels from redeployment, provision of “adequate” monitoring, clear routes of access 303 
to specialist advice and urgent review, and the ability to start, continue and monitor effective 304 
therapies and outcomes will need careful consideration. 305 
The high level of contact with IBD services by patients since the start of the pandemic 306 
demonstrates the ongoing requirement for suitably staffed advice lines and access to expert 307 
review, whether by telephone, video or face-to-face clinics.  308 
Wherever possible, arrangements should be made to facilitate some method of ongoing 309 
regular, scheduled MDT working, for discussion of complex or concerning cases needing 310 
consensus opinion. In addition, there will arguably be benefit to all team members of 311 
accessing peer and colleague support. Videoconferencing platforms provide a means to 312 
facilitate such discussions while ensuring staff can practise social distancing and, where 313 
possible and appropriate, work remotely. Where scheduled MDT meetings, either virtual or 314 
face to face, are no longer feasible due to changes in work schedules other models of 315 
delivering care could be considered.  Informal arrangements such as discussion by email 316 
involving a suitable mix of specialist can provide short term alternatives.  317 
There has been rapid uptake by services of telephone clinics, and some centres have instituted 318 
video consultations. Previous studies [15–17] have assessed the impact of telemedicine 319 
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systems in IBD assessing feasibility, patient acceptance, effectiveness and impact on health 320 
care utilization. However, there are several potential barriers [18] and further adoption and 321 
upscaling of tele-consultation tools are urgently warranted. There is an ongoing international 322 
survey of telemedicine in IBD in the COVID-19 era organised by the International 323 
Organisation for the study of IBD. 324 
IBD patients appear to be receptive to the idea of non-face-to-face review where appropriate, 325 
with low levels of non-attendance reported to telephone and virtual appointments.[19] 326 
Reviewing patients also provides an opportunity to check their understanding of the ongoing 327 
pandemic, the impact it has on them as individuals and any effect it may have on their 328 
treatment. This should promote adherence to therapy, as well as facilitating early 329 
management of disease flares. Future surveys should assess patients’ preferences for 330 
telemedicine as we plan services following the COVID-19 pandemic. 331 
IBD endoscopy practice during the ongoing COVID-19 pandemic appears to be broadly in 332 
line with national and international consensus [14,20–22]. Endoscopy services have been 333 
rationalised to provide the most urgent information for the safe care of patients such as in the 334 
management of acute severe colitis. Similarly, elective surgery has been stopped with a focus 335 
on emergency surgery for acute severe colitis, emergency small bowel resection and drainage 336 
for perianal sepsis. There are concerns about the potential impact of delaying elective 337 
endoscopies and operations in patients with IBD. Services will need to make plans for 338 
appropriate prioritisation of delayed procedures including those needing diagnosis of new 339 
IBD or and those needing surveillance to ensure safety in the post-pandemic era [22].  340 
Currently the UK consensus guidelines do not recommend cessation of therapies such as 341 
biologics and immunomodulators in IBD patients who currently do not have COVID-19 (8). 342 
In those who stop therapies during illness with SARS-CoV2 or following a positive test, 343 
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current guidelines recommend biologics and immunomodulators are recommenced soon after 344 
cessation of symptoms [8,9]. The IBD services surveyed here appear to have taken prompt 345 
action to ensure continuity of treatments in infusion units, but logistical challenges with 346 
location and delivery of treatments remain; a significant proportion of services reported 347 
difficulties in delivery of infusions. This may worsen as the pandemic progresses over time 348 
due to patient factors such as shielding, isolation due to contact and fears about safety  as well 349 
as staffing-related challenges depending of the duration of the pandemic or indeed new peaks 350 
in the pandemic . Adoption of subcutaneous therapies among patients starting biologic 351 
therapy may reduce the pressures on infusion units and reduce patient footfall in the hospital 352 
site. However, a concerning number are reporting difficulties in starting new home care 353 
treatments and also in the delivery of ongoing treatments, which needs addressing urgently. 354 
IBD advice lines are an immensely valuable resource for patients with IBD [23] and this is 355 
more so when elective activity has been curtailed as evidenced in our survey. The marked 356 
increase in the number of patients accessing IBD advice lines, coupled with a reduction in the 357 
number of staff in more than a quarter of services, is likely to impact provision of prompt 358 
support and advice to patients, who are understandably concerned about the potential impact 359 
of IBD and their medications during the COVID-19 pandemic. Services have attempted to 360 
provide more online support, but the unprecedented increase in number of contacts may 361 
prove overwhelming. It is likely that requests for advice regarding social distancing and 362 
shielding will reduce, but the number of patients contacting IBD advice lines for flare 363 
management may rise as routine outpatient clinics have been stopped or have limited access 364 
in many centres. 365 
Non-invasive assessment and monitoring of IBD is critical during the COVID-19 pandemic. 366 
Hence it is unfortunate that several services report cessation of faecal calprotectin services, 367 
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mainly due to concerns regarding risks to laboratory staff as, although faeco-oral 368 
transmission is not confirmed yet.  SARS-CoV-2  [24] has been detected in faeces even in 369 
asymptomatic patients with COVID-19; however, it is not clear if this represents live virus. 370 
One option for such services is to initiate and upscale the use of point-of-care faecal 371 
calprotectin testing [25]. A major concern highlighted by this survey is the significant 372 
reduction in both clinicians and specialist nurses available to care for IBD patients. More than 373 
50% of the respondents felt that the services would remain under-staffed and unable to meet 374 
the needs of IBD patients. Redeployment to frontline COVID-19 duties appears to be the 375 
main factor and this may need addressing at unit level with measures such as creation of a 376 
designated core team of clinicians and specialist nurses to deliver IBD care, as adopted by 377 
centres in Italy [26] . We should also ensure that, where the local COVID-19 situation 378 
permits, IBD specialist nurses and doctors are able to resume their responsibilities in IBD 379 
care. 380 
Our survey has some limitations. We could not capture responses of all IBD services in the 381 
UK. We were, however, able to reach out to approximately 70% of UK IBD services who 382 
registered for the recent unit and patient assessment of services under IBDUK 383 
(https://ibduk.org/services-map). The epidemic is at different stages across the UK, but as can 384 
be seen in figure 4, we have good geographic coverage of the country. It is possible that some 385 
of the most under-resourced IBD services may also have been less likely to have someone 386 
available to complete the survey. Finally, the rapidly evolving nature of data and guidelines 387 
relating to COVID-19 in IBD makes future assessment of service provision important to 388 
ensure equitable access to high quality IBD care across the country. 389 
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Conclusions 390 
In this survey, we provide a comparative reference to support consistency of care across the 391 
UK during a difficult time and to offer a template to centres in other countries which have yet 392 
to undergo such alterations. It is our hope that this will allow services to make suitable 393 
arrangements to maintain high quality uninterrupted care for patients with IBD. The ongoing 394 
COVID-19 pandemic has and may continue to pose myriad challenges to healthcare systems 395 
across the globe. IBD services in the UK and other countries will face unique challenges both 396 
during the peak and post-peak pandemic period with respect to responsive and responsible 397 
adaptation of service delivery. These are unprecedented and challenging times. Yet, even 398 
grim challenges present opportunities not in the least with insights gleaned from rapid 399 
adaptation of models of service delivery some of which, are likely to be also suitable in a 400 
post-COVID-19 world. Indeed, there may be opportunities for positive changes in IBD 401 
services resulting from this difficult time. 402 
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